Radiogel™ is an injectable hydrogel that delivers localized beta radiation to solid tumors without damaging surrounding healthy tissue. It’s currently under review with the U.S. FDA following successful clinical trials in India.
Localized tumor treatment with minimal side effects
Radiogel™ has officially filed its Investigational Device Exemption (IDE) with the U.S. Food & Drug Administration. Stay tuned as it progresses toward approval in the United States.
The Invention Story
This site is dedicated in part to the inventors of Radiogel, whose scientific vision helped create a hopeful future for cancer patients worldwide. Don’t ever Give Up! Follow the stock traded on NASDAQ symbol RDGL.